Myeloproliferative Neoplasms News

In this video, Lindsay A.M. Rein, MD, discussed the phase 1/phase 2 TP-3654 study into relapsed/refractory myelofibrosis, data from which she presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best available therapy in patients with high-risk polycythemia vera, according to data presented at ASH Annual Meeting.

SAN DIEGO — Patients with Philadelphia chromosome-negative accelerated- or blast-phase myeloproliferative neoplasms who received allogeneic hematopoietic stem cells had a longer median OS than those who did not, according to a study.

SAN DIEGO — Lower platelet count was identified as a significant predictor for ruxolitinib-induced moderate or severe thrombocytopenia in patients with myelofibrosis, according to research presented at ASH Annual Meeting and Exposition.

SAN DIEGO — The BET inhibitor BMS986158 has continued to be well tolerated in combination with ruxolitinib and fedratinib in patients with intermediate- or high-risk myelofibrosis, according to a study presented at ASH Annual Meeting.

In this video, John Mascarenhas, MD, discussed the RuxoBEAT study into ruxolitinib treatment in patients with polycythemia vera, which was presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the TRANSFORM-1 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, John Mascarenhas, MD, discussed the MANIFEST-2 study into combination therapies in myelofibrosis treatment, which was presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.